Focusing on patients with high bleeding risk undergoing PCI, this session presents contemporary evidence on prevalence, procedural strategies with different stent types, antiplatelet therapy considerations including diabetic and sex-specific outcomes, and novel technologies such as sirolimus-coated balloons and machine learning models for restenosis prediction.

This session provides an in-depth review of registries and clinical trials focused on transcatheter mitral valve replacement (TMVR). It presents data on annular and ventricular remodeling with the HighLife system, mid- to long-term valve performance, and innovations in transseptal TMVR using novel bioprostheses.

This session focuses on non-occlusive causes of acute coronary syndromes (ACS) when angiograms do not reveal clear pathology. It emphasizes the diagnostic value of intracoronary imaging for conditions such as MINOCA and spontaneous coronary artery dissection (SCAD), and discusses optimal treatment strategies and prognostic considerations.

This session explores the use of stentless percutaneous coronary interventions (PCI) employing drug-coated balloons (DCB) and bioresorbable scaffolds (BVS) in complex coronary scenarios. Through detailed case discussions, it addresses decision-making processes, technical considerations, and practical tips for successfully completing PCI without permanent stenting.

The present clinical case highlights some anatomical, functional, and devices-related features which may be used as red flag in the LAAO procedure planning due to prevent PA perforation, a rare but serious complication.

Mitral transcatheter edge-to-edge repair (M-TEER) has reshaped the prognosis for heart failure patients with secondary mitral regurgitation, but recurrence remains a real challenge when surgical options are off the table.

This case highlights an innovative use of an atrial flow regulator (AFR) to manage elevated left atrial...

Daniele Giacoppo reports the main results of the RENOVATE-COMPLEX-PCI trial presented by Joo-Yong Hahn, from the Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, in a Late-Breaking Trial session at the American College of Cardiology (ACC) 2023 / World...

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

Claudio Laudani and Daniele Giacoppo report the main results of the ILUMIEN IV trial presented by Ziad Ali, from the St. Francis Hospital, Roslyn, and Clinical Trials Center, Cardiovascular Research Foundation, New York, in a Hot Line session at the European Society of Cardiology congress 2023...